3,317 Shares in Jazz Pharmaceuticals PLC $JAZZ Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 3,317 shares of the specialty pharmaceutical company’s stock, valued at approximately $768,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. USA Financial Formulas bought a new position in Jazz Pharmaceuticals during the 1st quarter valued at $25,000. Pension & Wealth Management Advisors Inc. acquired a new position in shares of Jazz Pharmaceuticals during the 3rd quarter valued at $32,000. Ameritas Advisory Services LLC acquired a new position in shares of Jazz Pharmaceuticals during the 2nd quarter valued at $47,000. Westpac Banking Corp acquired a new position in shares of Jazz Pharmaceuticals during the 1st quarter valued at $51,000. Finally, Elevation Wealth Partners LLC raised its stake in shares of Jazz Pharmaceuticals by 156.4% in the 3rd quarter. Elevation Wealth Partners LLC now owns 259 shares of the specialty pharmaceutical company’s stock worth $60,000 after buying an additional 158 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Trending Headlines about Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz beat quarterly estimates, reporting $1.24 billion in revenue versus roughly $1.21 billion expected, with revenue up 10.4% year over year. Coverage also reported that the company raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, helping reinforce the growth outlook. Q3 results and outlook
• Positive Sentiment: RBC, Barclays, Morgan Stanley and JPMorgan issued favorable commentary or raised price targets after the results. The analyst optimism adds support to the stock’s post-earnings momentum. Barclays price-target update
• Neutral Sentiment: CEO Renée Galá sold 1,000 shares under a pre-arranged Rule 10b5-1 plan and retained 140,394 shares. Director Bruce Cozadd also sold 6,000 shares under a pre-arranged plan, while CAO Patricia Carr sold 1,413 shares and retained 6,512. These sales may draw investor attention, but planned transactions are not necessarily a signal about near-term business prospects. Insider transaction coverage

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Wall Street Zen downgraded Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday. Wells Fargo & Company raised their target price on Jazz Pharmaceuticals from $285.00 to $300.00 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. TD Cowen raised their target price on Jazz Pharmaceuticals from $275.00 to $300.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Robert W. Baird lifted their target price on Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a report on Tuesday, August 4th. Finally, Truist Financial boosted their price target on shares of Jazz Pharmaceuticals from $281.00 to $286.00 and gave the stock a “buy” rating in a research report on Wednesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $293.45.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, CEO Renée Galá sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $225.37, for a total value of $225,370.00. Following the transaction, the chief executive officer directly owned 140,394 shares in the company, valued at $31,640,595.78. The trade was a 0.71% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bruce Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $215.84, for a total value of $1,295,040.00. Following the completion of the transaction, the director owned 339,875 shares in the company, valued at $73,358,620. The trade was a 1.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 102,534 shares of company stock worth $25,185,243. 4.10% of the stock is owned by insiders.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ opened at $234.76 on Monday. The stock has a market capitalization of $15.07 billion, a price-to-earnings ratio of 79.85, a PEG ratio of 0.43 and a beta of 0.38. Jazz Pharmaceuticals PLC has a 1-year low of $128.80 and a 1-year high of $266.38. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.64 and a current ratio of 1.82. The company has a 50 day moving average price of $229.39 and a 200 day moving average price of $217.74.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.03) by $0.15. The company had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $1.21 billion. Jazz Pharmaceuticals had a return on equity of 16.88% and a net margin of 4.37%. The firm’s revenue was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $8.13 earnings per share. On average, research analysts anticipate that Jazz Pharmaceuticals PLC will post 11.08 EPS for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets.

Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.

Jazz expanded its portfolio through acquisitions, including the 2021 acquisition of GW Pharmaceuticals, which added Epidiolex and other cannabinoid-based medicines.